An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis

References

• Sieper J, Braun J, Rudwaleit M, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61 Suppl 3:iii8–18.
   PubMed Web of Science ®Google Scholar
• Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70:1921–1925.
   PubMed Web of Science ®Google Scholar
• Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum. 1995;38:499–505.
   PubMed Web of Science ®Google Scholar
• Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 1991;10:4025–4031.
   PubMed Web of Science ®Google Scholar
• Hiyama A, Yokoyama K, Nukaga T, et al. A complex interaction between Wnt signaling and TNF-α in nucleus pulposus cells. Arthritis Res Ther. 2013;15:R189.
   PubMed Web of Science ®Google Scholar
• Heiland GR, Appel H, Poddubnyy D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:572–574.
   PubMed Web of Science ®Google Scholar
• Senolt L, Hulejova H, Krystufkova O, et al. Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis. Ann Rheum Dis. 2012;71:71–74.
   PubMed Web of Science ®Google Scholar
• Uderhardt S, Diarra D, Katzenbeisser J, et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69:592–597.
   PubMed Web of Science ®Google Scholar
• Lin Z, Bei JX, Shen M, et al. A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet. 2012;44:73–77.
   Web of Science ®Google Scholar
• Qian B-P, Wang X-Q, Qiu Y, et al. Association of receptor activator of nuclear factor-kappaB ligand (RANKL) gene polymorphisms with the susceptibility to ankylosing spondylitis: a case-control study. J Orthop Sci. 2014;19:207–212.
   PubMed Web of Science ®Google Scholar
• Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106:1481–1488.
   PubMed Web of Science ®Google Scholar
• Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:Cd005468.
   PubMed Web of Science ®Google Scholar
• Davis JC Jr., van der Heijde DM, Dougados M, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol. 2005;32:1751–1754.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63:665–670.
   PubMed Web of Science ®Google Scholar
• Gossec L, Dougados M, D’Agostino MA, et al. Fatigue in early axial spondyloarthritis. Results from the French DESIR cohort. Joint Bone Spine. 2015;83(4):427–431.
   Web of Science ®Google Scholar
• Bedaiwi M, Sari I, Thavaneswaran A, et al. Fatigue in ankylosing spondylitis and nonradiographic axial spondyloarthritis: analysis from a longitudinal observation cohort. J Rheumatol. 2015;42:2354–2360.
   PubMed Web of Science ®Google Scholar
• Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18–24.
   PubMed Web of Science ®Google Scholar
• Navarro-Compan V, Ramiro S, Landewe R, et al. Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort. Ann Rheum Dis. 2015;75(5):874–878.
   Web of Science ®Google Scholar
• Machado P, Landewe RB, Braun J, et al. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis. 2012;71:2002–2005.
   PubMed Web of Science ®Google Scholar
• Lambert RGW, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis. Arthritis Rheum. 2007;56:4005–4014.
   PubMed Web of Science ®Google Scholar
• Braun J, Landewé R, Hermann K-GA, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum. 2006;54:1646-52.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Wichuk S, Chiowchanwisawakit P, et al. Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis. Arthritis Res Ther. 2014;16:R100.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis. 2008;67:1276–1281.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis. 2012;71:878–884.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Sorensen IJ, Hermann KG, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis. 2010;69:1065–1071.
   PubMed Web of Science ®Google Scholar
• Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:973–981.
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol. 2009;36:801–808.
   PubMed Web of Science ®Google Scholar
• Turina MC, Sieper J, Yeremenko N, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 2014;73:1746–1748.
   PubMed Web of Science ®Google Scholar
• Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2011;13:R94.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Koenig AS, Jones H, et al. Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials. J Rheumatol. 2015;42:1418–1426.
   PubMed Web of Science ®Google Scholar
• Sieper J, Lenaerts J, Wollenhaupt J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST part 2. Ann Rheum Dis. 2014;73:108–113.
   PubMed Web of Science ®Google Scholar
• Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1. Ann Rheum Dis. 2014;73:101–107.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Haibel H, Fritz C, et al. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013;15:R67.
   PubMed Web of Science ®Google Scholar
• Davis JC Jr., van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. 2008;67:346–352.
   PubMed Web of Science ®Google Scholar
• Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008;59:1270–1278.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Braun J, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Ann Rheum Dis. 2015;74:757–761.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922–929.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis. 2010;69:2002–2008.
   PubMed Web of Science ®Google Scholar
• Mease P, Sieper J, van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol. 2015;67:914–923.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72:1149–1155.
   PubMed Web of Science ®Google Scholar
• De Vries MK, Brouwer E, van der Horst-Bruinsma IE, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis. 2009;68:1787–1788.
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Wei JC, Nurmohamed MT, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis. 2015;74:396–401.
   PubMed Web of Science ®Google Scholar
• Kneepkens EL, Krieckaert CL, van der Kleij D, et al. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis. 2015;74:1825–1829.
   PubMed Web of Science ®Google Scholar
• Jung SM, Kim H-S, Kim H-R, et al. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. Int Immunopharmacol. 2014;21:20–25.
   PubMed Web of Science ®Google Scholar
• Mulleman D, Lauféron F, Wendling D, et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther. 2011;13:R82.
   PubMed Web of Science ®Google Scholar
• Delaunay C, Farrenq V, Marini-Portugal A, et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol. 2005;32:2183–2185.
   PubMed Web of Science ®Google Scholar
• Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393–1397.
   PubMed Web of Science ®Google Scholar
• Coates LC, Cawkwell LS, Ng NW, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:897–900.
   PubMed Web of Science ®Google Scholar
• Lie E, van der Heijde D, Uhlig T, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70:157–163.
   PubMed Web of Science ®Google Scholar
• Gulyas K, Bodnar N, Nagy Z, et al. Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis. Eur J Health Econ. 2014;15 Suppl 1:S93–S100.
   PubMed Web of Science ®Google Scholar
• Ciurea A, Exer P, Weber U, et al., Rheumatologists of Swiss Clinical Quality Management Program for Axial S. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss clinical quality management cohort. Arthritis Res Ther. 2016;18:71.
   PubMed Web of Science ®Google Scholar
• van Herwaarden N, Den Broeder AA, Jacobs W, et al. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev. 2014;9:Cd010455.
   PubMed Web of Science ®Google Scholar
• Jois RN, Leeder J, Gibb A, et al. Low-dose infliximab treatment for ankylosing spondylitis–clinically- and cost-effective. Rheumatology (Oxford). 2006;45:1566–1569.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Salonen D, Inman RD, et al. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol. 2010;37:1728–1734.
   PubMed Web of Science ®Google Scholar
• Inman RD, Maksymowych WP, Group CS. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010;37:1203–1210.
   PubMed Web of Science ®Google Scholar
• Navarro-Compan V, Moreira V, Ariza-Ariza R, et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol. 2011;30:993–996.
   PubMed Web of Science ®Google Scholar
• Lee J, Noh J-W, Hwang JW, et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin Rheumatol. 2010;29:1149–1154.
   PubMed Web of Science ®Google Scholar
• Zavada J, Uher M, Sisol K, et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis. 2016;75(1):96–102.
   Google Scholar
• Plasencia C, Kneepkens EL, Wolbink G, et al. Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity. J Rheumatol. 2015;42:1638–1646.
   PubMed Web of Science ®Google Scholar
• Arends S, van der Veer E, Kamps FB, et al. Patient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol. 2015;33:174–180.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum. 2012;64:1388–1398.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Heldmann F, Callhoff J, et al. Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography. Ann Rheum Dis. 2014;73:1819–1825.
   PubMed Web of Science ®Google Scholar
• Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013;65:2645–2654.
   PubMed Web of Science ®Google Scholar